Sequential Capecitabine/Temozolomide and Sunitinib Treatment in Patients With Metastatic Well-Differentiated Grade 1/Grade 2 Pancreatic Neuroendocrine Tumors

MLA

Wenquan Wang, et al. “Sequential Capecitabine/Temozolomide and Sunitinib Treatment in Patients With Metastatic Well-Differentiated Grade 1/Grade 2 Pancreatic Neuroendocrine Tumors.” Endocrine Practice, vol. 28, Mar. 2022, pp. 292–97. EBSCOhost, https://doi.org/10.1016/j.eprac.2021.08.008.

APA

Wenquan Wang, Hao Li, Wu-Hu Zhang, He-Li Gao, Long-Yun Ye, Quanxing Ni, Hua-Xiang Xu, Jia Dong, & Liang Liu. (2022). Sequential Capecitabine/Temozolomide and Sunitinib Treatment in Patients With Metastatic Well-Differentiated Grade 1/Grade 2 Pancreatic Neuroendocrine Tumors. Endocrine Practice, 28, 292–297. https://doi.org/10.1016/j.eprac.2021.08.008

Chicago

Wenquan Wang, Hao Li, Wu-Hu Zhang, He-Li Gao, Long-Yun Ye, Quanxing Ni, Hua-Xiang Xu, Jia Dong, and Liang Liu. 2022. “Sequential Capecitabine/Temozolomide and Sunitinib Treatment in Patients With Metastatic Well-Differentiated Grade 1/Grade 2 Pancreatic Neuroendocrine Tumors.” Endocrine Practice 28 (March): 292–97. doi:10.1016/j.eprac.2021.08.008.